Fenamifuril is an antiinflammatory and antirheumatic agent.

Naproxol is an aromatic ether in which the substituents on oxygen are 6-[(2S)-1-hydroxypropan-2-yl]-2-naphthyl and methyl. It has a role as a non-steroidal anti-inflammatory drug, a non-narcotic analgesic and an antipyretic.

Girisopam (GYKI 51189), a 2,3-benzodiazepine, is a compound with anxiolytic and antipsychotic action. It has shown these effects in several animal models. Girisopam differs from the traditional 1,4-benzodiazepines because of its selective anxiolytic action without muscle relaxant and anticonvulsive activity, and because it does not have affinity for 1,4-benzodiazepine receptors. Antidepressant activity of girisopam was also reported. The binding site of girisopam in neuronal cells in the central nervous system is located exclusively to the basal ganglia. Because the danger of tolerance and dependence is lower for 2,3-benzodiazepine than 1,4-benzodiazepines, girisopam may potentially be used in treatment of addiction and affective disorders. No clinical trials were conducted in the US.

Naluzotan (PRX-00023), a small molecule, non-azapirone, dual serotonin (5-HT)1A receptor agonist and sigma-1 receptor antagonist, is under development with Proximagen for the treatment of epilepsy. In previous clinical trials, the compound was shown to be safe and well-tolerated in over 400 patients. Epilepsy patients with localisation-related epilepsy have reduced 5-HT1a receptor binding as indicated by positron emission tomography (PET scan). It is thought that by increasing neurotransmitter activity at 5-HT1a receptor sites, seizure incidence and severity may be decreased.

Sulazepam is a desmethylbenzodiazepine. It is the thioamide derivative of diazepam. It has sedative, muscle relaxant, hypnotic, anticonvulsant and anxiolytic properties like those of other benzodiazepines. Sulazepam in vivo in experimental animals undergoes enzymic desulfonation, demethylation, and [3C] hydroxylation, with the formation of basic metabolites: diazepam, desmethyldiazepam, and oxazepam.

Indocate is indole derivative and monoamine oxidase inhibitor with peripheral antiserotonin properties.

Raxofelast (IRFI 016) is a hydrophilic vitamin E-like antioxidant, that was developed to maximize the antioxidant potency of phenols related to vitamin E. It has been investigated as a mucoactive drug, a type of drug that is used for treatment of respiratory diseases. Also, in diabetic mice, raxofelast was shown to improve wound healing to a level close to that seen in healthy mice, and in another study it improved clinical outcomes in experimental burn wounds. In a rat model of myocardial damage, raxofelast was found to be a useful drug to reduce heart attacks. This compound has good bioavailability and physicochemical properties. No clinical trials have been conducted.

Ralitoline is thiazolidinylidene derivative patented by Goedecke A.-G. as an anticonvulsant. In preclinical models, ralitoline blocks sustained repetitive firing of sodium action potentials with effects on firing activity triggered by spontaneous excitatory postsynaptic potentials at higher concentrations. No effects on iontophoretic GABA and glutamate responses were noted. Ralitoline inhibit the binding of tritiated batrachotoxinin A 20-alpha-benzoate ([3H]BTX-b) to rat brain synaptosomes. In healthy volunteers with single and multiple doses (50-200 mg). ralitoline is well absorbed by oral ingestion, with peak plasma concentrations occurring approximately 2-3 hr postdose. Approximately 2 weeks of administration of ralitoline had no effect on the steady-state kinetics of phenytoin or phenobarbitone in healthy volunteers.

Lotucaine is a local anesthetic.